New obesity drug candidate cagrilintide tested in Head-to-Head trial

NCT ID NCT07597018

Recruiting now Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two versions of the experimental drug cagrilintide in 234 adults with overweight or obesity. Participants receive either version D or version B by injection once a week for about 6 months. The goal is to see how the drug is processed in the body, not to measure weight loss directly.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cagrilintide
What this could lead to: If successful, this study could help determine which version of cagrilintide is better for weight management, potentially leading to a new treatment option for obesity.
What could go wrong: This is an early Phase 1 trial focused on how the drug behaves in the body, not on weight loss or safety. The results may not lead to an approved treatment, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY OVERWEIGHT

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Parexel International GmbH
RECRUITING

Berlin, 14050, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.